VolitionRx reports Q2 2026 results, cites licensing talks and Sysmex collaboration

VolitionRx Limited announced financial results and a business update for the second quarter of 2026 on August 13, 2026. Cameron Reynolds, President and Group Chief Executive Officer, said the company is talking with more than a dozen leading diagnostic and liquid biopsy companies, including technology evaluations, aiming for licensing agreements and other deals that could bring upfront payments, royalties, or other recurring revenue, with negotiations at different stages across the company's product pillars.¹

Volition also pointed to its collaboration with Sysmex Corporation, described as a global leader in in vitro diagnostics for hemostasis and thrombosis, in an area where Neutrophil Extracellular Traps (NETs) are relevant.¹ On the veterinary side, the company said that in May it submitted for peer review a clinical manuscript on its Nu.Q Vet feline prototype assay for detecting lymphoma in cats, a third species for the platform, with publication expected to unlock a $5 million contractual milestone payment.¹

In lung cancer diagnostics, Volition said it is working with the Hospices Civils de Lyon on a reimbursement submission for Nu.Q Lung Cancer.¹ The company also referenced publication of its first peer-reviewed paper on its Capture-Seq liquid biopsy technology.¹

On financials, first-half 2026 revenue was $1.4 million, up 112% from the first half of 2025, while second-quarter 2026 revenue was about $0.4 million, in line with the same period in 2025.¹ Operating expenses in the quarter fell 32% year over year, operating loss was $4.2 million (down 34%), and net cash used in operating activities was $5.2 million, 18% lower than the prior-year quarter.¹ The quarter's cash receipts included $1.2 million in net proceeds from at-the-market equity sales and $4.1 million in net proceeds from a confidentially marketed public offering of shares and warrants.¹